|
WO2021076866A1
|
|
Generation of induced pluripotent stem cells with polycistronic sox2, klf4, and optionally c-myc
|
|
WO2021061909A1
|
|
Method of targeting neuronal apoe to treat a neurocognitive disorder
|
|
WO2021050822A1
|
|
Modified bacterial retroelement with enhanced dna production
|
|
WO2020154174A1
|
|
Compositions and methods for reactivating latent immunodeficiency virus and/or treating immunodeficiency virus infection
|
|
WO2020051452A2
|
|
Hiv or hcv detection with crispr-cas13a
|
|
KR20200094795A
|
|
Generation of induced pluripotent cells by CRISPR activation
|
|
EP3687982A1
|
|
Methods of treating neurodegeneration
|
|
EP3601526A1
|
|
Induced totipotent stem cells and methods for making and using the same
|
|
EP3529622A1
|
|
Genetically encoded cell death indicators and methods of use
|
|
EP3474868A1
|
|
Engineered cardiomyocytes and uses thereof
|
|
MX2018011875A
|
|
Enhanced direct cardiac reprogramming.
|
|
WO2017147381A1
|
|
Generation of expandable cardiovascular progenitor cells
|
|
EP3331988A1
|
|
Chemical reprogramming to generate neuronal cells
|
|
WO2016196259A1
|
|
Suicide stem cell support cell line and methods for making and using the same
|
|
EP3292198A1
|
|
Reversion of primed pluripotent stem cells to naive pluripotent stem cells
|
|
EP3280425A1
|
|
Methods for inducing cell division of postmitotic cells
|
|
US2016186141A1
|
|
Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes
|
|
EP3177709A1
|
|
Reversible stencils for fabricating micro-tissues
|
|
EP3116516A1
|
|
Inducing brown fat fate and function
|
|
EP3091984A1
|
|
Substituted benzoxazine and related compounds
|
